Natalie A Schwehr1, Karen M Kuntz2, Eva A Enns2, Nathan D Shippee2, Elaine Kingwell3, Helen Tremlett3, Adam F Carpenter4,5, Mary Butler2. 1. Division of Health Policy and Management, University of Minnesota School of Public Health, MMC729, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. schwe425@umn.edu. 2. Division of Health Policy and Management, University of Minnesota School of Public Health, MMC729, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. 3. Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada. 4. Department of Neurology, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA. 5. Brain Sciences Center, VA Medical Center, 1 Veterans Drive, Minneapolis, MN, 55417, USA.
Abstract
BACKGROUND: For older adults with relapsing-onset multiple sclerosis (MS), limited information is available to inform if, or when, disease-modifying drugs (DMDs) may be safely discontinued. OBJECTIVE: The aim of this study was to project the outcomes of DMD discontinuation among older adults with relapsing-onset MS. METHODS: We projected the 10-year outcomes of discontinuation of a DMD (interferon-β, fingolimod, or natalizumab) among older adults (aged 55 or 70 years) who were relapse-free for 5 or more years and had not reached an Expanded Disability Status Scale (EDSS) score of 6. Outcomes included the percentage of people who had at least one relapse or reached EDSS 6, and quality-adjusted life-years (QALYs), which incorporated both relapses and disability. We used a simulation modeling approach. With increased age, relapses decreased and the effectiveness of DMDs for disability outcomes also decreased. RESULTS: We found lower projected benefits for DMD continuation at 70 years of age than at 55 years of age. Compared with discontinuation, the projected benefit of DMD continuation ranged from 0.007 to 0.017 QALYs at 55 years of age and dropped to 0.002-0.006 at 70 years of age. The annual projected benefits of DMD continuation (0.1-3.0 quality-adjusted life-days) were very low compared with typical patient preferences regarding treatment burden. CONCLUSION: The benefits of DMDs may not be substantial among older adults with relapsing-onset MS. Direct clinical evidence remains limited and the decision of whether to discontinue a DMD should also take into account patient preferences. It is important to gain a better understanding of how age-related changes in the trajectory of relapsing-onset MS affect treatment effectiveness among older adults.
BACKGROUND: For older adults with relapsing-onset multiple sclerosis (MS), limited information is available to inform if, or when, disease-modifying drugs (DMDs) may be safely discontinued. OBJECTIVE: The aim of this study was to project the outcomes of DMD discontinuation among older adults with relapsing-onset MS. METHODS: We projected the 10-year outcomes of discontinuation of a DMD (interferon-β, fingolimod, or natalizumab) among older adults (aged 55 or 70 years) who were relapse-free for 5 or more years and had not reached an Expanded Disability Status Scale (EDSS) score of 6. Outcomes included the percentage of people who had at least one relapse or reached EDSS 6, and quality-adjusted life-years (QALYs), which incorporated both relapses and disability. We used a simulation modeling approach. With increased age, relapses decreased and the effectiveness of DMDs for disability outcomes also decreased. RESULTS: We found lower projected benefits for DMD continuation at 70 years of age than at 55 years of age. Compared with discontinuation, the projected benefit of DMD continuation ranged from 0.007 to 0.017 QALYs at 55 years of age and dropped to 0.002-0.006 at 70 years of age. The annual projected benefits of DMD continuation (0.1-3.0 quality-adjusted life-days) were very low compared with typical patient preferences regarding treatment burden. CONCLUSION: The benefits of DMDs may not be substantial among older adults with relapsing-onset MS. Direct clinical evidence remains limited and the decision of whether to discontinue a DMD should also take into account patient preferences. It is important to gain a better understanding of how age-related changes in the trajectory of relapsing-onset MS affect treatment effectiveness among older adults.
Authors: A Shirani; Y Zhao; M E Karim; J Petkau; P Gustafson; C Evans; E Kingwell; M L van der Kop; J Oger; H Tremlett Journal: Eur J Neurol Date: 2013-12-18 Impact factor: 6.089
Authors: M Vercellino; A Romagnolo; A Mattioda; S Masera; C Piacentino; A Merola; A Chiò; R Mutani; P Cavalla Journal: Acta Neurol Scand Date: 2008-08-05 Impact factor: 3.209
Authors: Bruce A C Cree; Jill A Hollenbach; Riley Bove; Gina Kirkish; Simone Sacco; Eduardo Caverzasi; Antje Bischof; Tristan Gundel; Alyssa H Zhu; Nico Papinutto; William A Stern; Carolyn Bevan; Andrew Romeo; Douglas S Goodin; Jeffrey M Gelfand; Jennifer Graves; Ari J Green; Michael R Wilson; Scott S Zamvil; Chao Zhao; Refujia Gomez; Nicholas R Ragan; Gillian Q Rush; Patrick Barba; Adam Santaniello; Sergio E Baranzini; Jorge R Oksenberg; Roland G Henry; Stephen L Hauser Journal: Ann Neurol Date: 2019-03-30 Impact factor: 10.422
Authors: Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann Journal: Brain Date: 2009-03-31 Impact factor: 13.501
Authors: Heidi Lindroth; Babar A Khan; Janet S Carpenter; Sujuan Gao; Anthony J Perkins; Sikandar H Khan; Sophia Wang; Richard N Jones; Malaz A Boustani Journal: Ann Am Thorac Soc Date: 2020-09